BioSpace News Archive

Ascentage Pharma announced that the Center for Drug Evaluation of the China National Medical Products Administration has approved a registrational pivotal Phase III study of olverembatinib, Ascentage Pharma’s lead drug candidate, in combination with chemotherapy comparing imatinib in combination with chemotherapy for treatment of patients with naïve Philadelphia chromosome-positive acute lymphoblastic leukemia.

Rigel Pharmaceuticals, Inc. announced that it has granted awards pursuant to the Rigel Pharmaceuticals, Inc. Inducement Plan, approved by the Compensation Committee of Rigel’s Board of Directors and granted as an inducement material to employees’ entering into employment with Rigel, in accordance with NASDAQ Listing Rule 5635.

Syros Pharmaceuticals, a biopharmaceutical company committed to advancing new standards of care for the frontline treatment of hematologic malignancies, announced the grant of a restricted stock unit award for 9,000 shares of Syros common stock to one newly hired employee in connection with commencing employment with Syros.

ASLAN Pharmaceuticals (“ASLAN”, Nasdaq: ASLN), a clinical-stage, immunology-focused biopharmaceutical company developing innovative treatments to transform the lives of patients, will host a webcast to discuss the topline data from the global Phase 2b TREK-AD trial of eblasakimab in patients with moderate-to-severe atopic dermatitis on July 6, 2023, at 8:30 am ET.

Brii Biosciences Limited announced that it has entered into license agreements with VBI Vaccines, Inc., expanding the companies’ collaboration in the hepatitis B virus field.

Ceapro Inc. announced today that Gilles Gagnon, President and Chief Executive Officer of Ceapro and Dr. Vincent W. Li, Chief Operating Officer and Scientific Director of the Angiogenesis Foundation will participate in the Virtual Investor Summer Spotlight Series on Wednesday, July 12, 2023 at 1:00 PM ET.

Visiox Pharmaceuticals, Inc. today announced the expansion of its commercial team with the appointment of Sanjay Malieckal as Vice President of Sales and Marketing, who brings over two decades of ophthalmic commercial experience.

Panavance Therapeutics Inc. today announced that Greg Bosch, Chairman and CEO, James Costin, M.D., Head of Research & Development, José Iglesias, M.D., Chief Medical Officer, and Ben Steinmetz, Chief Commercial Officer of Panavance Therapeutics will participate in the Virtual Investor Summer Spotlight Series on Thursday, July 13, 2023 at 2:00 PM ET.

Adolore Biotherapeutics today announced that Roelof Rongen, CEO and Roy Levitt, MD, Founder and Executive Chairman of Adolore, will participate in the Virtual Investor Summer Spotlight Series on Tuesday, July 11, 2023.

Abbott (NYSE: ABT) today announced that the U.S. Food and Drug Administration (FDA) has approved the AVEIR™ dual chamber (DR) leadless pacemaker system, the world’s first dual chamber leadless pacing system that treats people with abnormal or slow heart rhythms.